Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
13 p, 1.6 MB Pembrolizumab as consolidation strategy in patients with multiple myeloma : Results of the GEM-pembresid clinical trial / Puig, N. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; Corchete-Sánchez, L.A. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; Pérez-Morán, J.J. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; Dávila, J. (Complejo Asistencial de Ávila. Hematology Department) ; Paíno, T. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; de la Rubia, J. (Hematology Service. University Hospital Peset and Internal Medicine. School of Medicine and Dentistry. Catholic University of Valencia) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martín-Sánchez, J. (Hematology Department. Hospital Universitario Virgen del Rocío) ; de Arriba, F. (Servicio de Hematología y Oncología Médica. Hospital Universitario Morales Meseguer. IMIB-Arrixaca. Universidad de Murcia) ; Bladé, J. (Hematology Department. Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi I Sunyer) ; Blanchard, M.J. (Hematology Department. Hospital Ramón y Cajal) ; González-Calle, V. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; García-Sanz, R. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; Paiva, B. (Centro de Investigación Médica Aplicada. Instituto de Investigación Sanitaria de Navarra. Clínica Universidad de Navarra. CIBERONC) ; Lahuerta, J.J. (Centro de Investigación Biomédica en Red Cáncer (CIBERONC). Instituto de Investigación. Hospital Universitario 12 de Octubre) ; San-Miguel, J.F. (Centro de Investigación Médica Aplicada. Instituto de Investigación Sanitaria de Navarra. Clínica Universidad de Navarra. CIBERONC) ; Mateos, M.V. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ; Ocio, E.M. (Hospital Universitario Marqués de Valdecilla (IDIVAL). Universidad de Cantabria) ; Universitat Autònoma de Barcelona
PD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first-or second-line treatment. [...]
2020 - 10.3390/cancers12123615
Cancers, Vol. 12 Núm. 12 (december 2020) , p. 1-13  
2.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T (St István and St László Hospital of Budapest) ; Petrucci,M.T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K.L. (University College London Cancer Institute) ; Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ; Pour, L (University Hospital Ostrava) ; Dimopoulos, M.A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (Southampton General Hospital, Hampshire, UK) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitario La Fe, València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.